Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TILT-123 + Pembrolizumab in checkpoint inhibitor refractory NSCLC
NCT06125197Phase 1Active, not recruiting
- Sponsor
- TILT Biotherapeutics
- Start
- Jul 2024
- Primary completion
- Jan 2026
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Ad5/3-E2F-D24 in non-small cell lung cancer (NSCLC), sponsored by TILT Biotherapeutics. Primary endpoints: Dose-Limiting Toxicity and Adverse Events. Started Jul 2024; status: active, not recruiting.
02
Drugs
Ad5/3-E2F-D24
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06125197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06125197.